Peer-influenced content. Sources you trust. No registration required. This is HCN.

Monthly Prescribing Reference (MPR)July 2022 Notable Drug Approvals

FDA approved new indications for these drugs in July, include a Janus kinase inhibitor and a phosphodiesterase-4 inhibitor for use in dermatology, a carbonic anhydrase inhibitor for partial-onset seizures, and an expanded indication for the TKI crizotinib.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form